Actively Recruiting
HiLoGlio Organoid Study: A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors
Led by Maastricht Radiation Oncology · Updated on 2026-01-27
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
M
Maastricht Radiation Oncology
Lead Sponsor
M
Maastricht University Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying high-grade and low-grade gliomas to better understand why these brain tumors behave differently within and between patients and why current treatments often fail. This research aims to uncover how gliomas become more aggressive, spread, and resist therapies by using patient-derived organoids (PDOs), which are three-dimensional tumor cultures grown from patients' tumor tissue. The ultimate goal is to develop personalized tumor models to test new treatments that could improve survival and quality of life for glioma patients. The study involves collecting tumor tissue from patients diagnosed with either low-grade or high-grade glioma who are scheduled for tumor removal surgery. The tissue will be used to grow PDOs that closely resemble the original tumors. Researchers will analyze these organoids for their genetic, epigenetic, and cellular characteristics and test how they respond to standard and new treatments, including chemotherapy, immunotherapy, and radiation with photons or protons. Additionally, the study will explore interactions between tumor organoids and immune cells, as well as mechanisms of tumor cell death and progression. Participants will undergo tumor resection and blood sampling at baseline to provide tissue for organoid creation and analysis. The research team will monitor the phenotypic and molecular profiles of the organoids to understand tumor behavior and treatment response. This observational study does not involve experimental treatments for participants. Participation involves providing tumor tissue during planned surgery, with no additional treatment changes. The study will continue until December 2028, focusing on advancing knowledge to guide future glioma therapies.
CONDITIONS
Brief Title
A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- MRI diagnosis of low grade glioma (LGG) or high grade glioma (HGG)
- Age 18 years or older
- Patient is eligible for a resection of the tumor
You will not qualify if you...
- Contra-indication for neurosurgical resection of the tumor
- Incapacitated patient, unable to give informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - At time of tumor resection
Participants undergo tumor resection and blood sampling to establish patient-derived organoids and characterize tumor profiles.
1 visit (in-person)
Duration - Up to study completion
Participants are observed following tumor resection to study tumor characteristics and mechanisms related to treatment resistance and tumor progression.
Trial Site Locations
Total: 1 location
1
Maastricht Radiation Oncology
Maastricht, Limburg, Netherlands, 6229ET
Actively Recruiting
Research Team
A
Annika Noordink, Msc
C
Chantal Overhof
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here